Drugs / ABS-1230
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07156201 | Aug 2025 → Mar 2026 overdue | — | Actio Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07600736 | May 2026 → Jan 2027 expected | epilepsy, early-onset | Actio Biosciences, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABS-1230 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07600736 ↗ |
| Route | Oral | “ABS-1230 given orally” NCT07156201 ↗ |